Most MSI cancers are sporadic and account for approximately 90% of the MSI EC cases and 80% of the MSI CRC cases, which most often develops through acquired MLH1 promoter hypermethylation [4, 5]. This evidence concerns the gene MLH1 and colorectal carcinoma.